17,261 trials
Congenital Adrenal Hyperplasia · 21-Hydroxylase Deficiency · Adrenogenital Syndrome
Primary: Chronocort vs. Cortef Cortisol Concentrations (AUC Over 24 Hours - Time Points 0,.5,1,1.5,2,3,4,5,6,7,8,10,10.5,11, 11.5,12,13,15,17,17.5,18,18.5,19,20,22,24 Post Dose)…
Behcet Syndrome
Primary: Number of Oral Ulcers at Day 85 — 2.0; 0.4 ulcers/participants — p=<0.0001
Chronic Stable Angina
Primary: Change in Total Exercise Time (Seconds) — 24.3; 18.2; 33.9; 11.9 second
Pancreatic Cancer
Primary: The Maximum Tolerated Radiation Dose — 55 Gray (Gy)
Cardiomyopathy, Dilated
Primary: Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Month 6 — 35.4; 29.4; 35.0; 32.4 Percentage of blood pumped out
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With at Least One Skin Rash (Folliculitis) of Any Grade During the First 4 Months of Treatment — 71.2; 80.8 percentage of participants — p=0.175
Pancreatic Cancer
Primary: Patients Alive — 10 participants
Circadian Rhythm Sleep Disorders
Primary: Circadian Phase Shift — -0.48; 0.18; -1.14; -0.50 Hours
Fuchs' Dystrophy · Bullous Keratopathy
Primary: Number of Eyes With Immunologic Graft Rejection Episodes — 2; 0 eyes — p=0.17
Prostate Cancer
Primary: Time to Progression (TTP) — 2.5 months
Melanoma
Primary: Objective Response Rate (ORR) of PV-10 Treated Lesions — 51.3 percentage of participants
Diffuse Large B-Cell Lymphoma
Primary: Objective Response Rate — 2; 0 Patients
Stress Disorders · Post-Traumatic
Primary: Change in CAPS Score From Baseline to Week 24 — -16.3; -12.5 units on a scale
Leishmaniasis, Cutaneous
Primary: Final Clinical Cure for Index Lesions — 11; 9 participants
Childhood Burkitt Lymphoma · Childhood Diffuse Large Cell Lymphoma · Childhood Immunoblastic Large Cell Lymphoma
Primary: Grade ≥ 3 Stomatitis — 4; 6; 41; 34 participants